MetaVia Inc. MetaVia Inc.

MetaVia Inc.

MTVA

Hisse Senetlerindeki Sıralama #33006
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Hisse Fiyatı
$1.24
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$8.17M
Değişim (1 gün)
-1.59%
Değişim (1 yıl)
-23.93%
Ülke
US
Ticaret MetaVia Inc. (MTVA)

Kategori

Healthcare
MetaVia Inc. (MTVA) için temettü verimi geçmişi
MetaVia Inc. (hisse sembolü: MTVA) temettü verimi (TTM) 2023-12-31 itibariyle: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
MetaVia Inc. (MTVA) için 2014 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL